

Childhood Cancer Survivor Study BioPathology Processes

Sue Hammond MD

Nationwide Children's Hospital, Columbus, Ohio

- I. Confirmation of self-reported second malignancies
- II. Receive, process, and store paraffin material
- III. Provide paraffin material to investigators with approved projects

CCSS Confirmation of SMNs

- Majority of second malignancies are self-reported
- These reports are first screened by Joe Neglia
- Pathology reports are pursued for likely SMNs
- Pathology reports are reviewed and categorized by Sue Hammond (in original cohort ~ 50% confirmed)
- A final review is performed by Joe Neglia
- For a minority of cases, a second condition is confirmed by either other medical records or the National Death Index

Re –request of SMN material from original cohort, Spring 2015

Limited to breast and thyroid cancers.

Institutions much more likely to charge for materials than previously.

SPRING 2015 PILOT

Pilot
N=42
(38 participants)

20 (48%)
Block to
return

14 (33%)
Block to
keep

6 (15%)
Unstained
slides

2 (5%)
H&E slides
only

Childhood Cancer Survivor Study Paraffin Tissue Archive May 2015

SMN diagnosis	N	Total N = 258	
• Breast cancer	71	Other CA	14
• Thyroid cancer	46	Melanoma	9
• Meningiomas	39	Lymphoma/	14
• Sarcomas	23	Leukemia	
• Malignant CNS	19	NMSC	5
• AdenoCA	12	other/unk	6

Upcoming CCSS Pathology Changes

- Michael Arnold MD PhD
Pediatric Pathologist, Nationwide Children's
– will oversee SMN pathology review and
– CCSS Paraffin Tissue Archive
- Proposal in development for Logistics of CCSS Paraffin Archive to be done by the BioPathology Center at Nationwide Children's
- Nilsa C. Ramirez MD, Director